- Home
- UAMY vs SPRO Comparison
UAMY vs SPRO Comparison
Compare UAMY & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UAMY
- SPRO
- Stock Information
- Founded
- UAMY 1968
- SPRO 2013
- Country
- UAMY United States
- SPRO United States
- Employees
- UAMY N/A
- SPRO N/A
- Industry
- UAMY Metal Fabrications
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- UAMY Industrials
- SPRO Health Care
- Exchange
- UAMY Nasdaq
- SPRO Nasdaq
- Market Cap
- UAMY 74.2M
- SPRO 63.0M
- IPO Year
- UAMY N/A
- SPRO 2017
- Fundamental
- Price
- UAMY $1.93
- SPRO $1.05
- Analyst Decision
- UAMY Strong Buy
- SPRO Buy
- Analyst Count
- UAMY 2
- SPRO 3
- Target Price
- UAMY $1.75
- SPRO $5.00
- AVG Volume (30 Days)
- UAMY 7.2M
- SPRO 205.6K
- Earning Date
- UAMY 11-12-2024
- SPRO 11-14-2024
- Dividend Yield
- UAMY N/A
- SPRO N/A
- EPS Growth
- UAMY N/A
- SPRO N/A
- EPS
- UAMY N/A
- SPRO 0.06
- Revenue
- UAMY $10,219,826.00
- SPRO $106,455,000.00
- Revenue This Year
- UAMY N/A
- SPRO N/A
- Revenue Next Year
- UAMY N/A
- SPRO N/A
- P/E Ratio
- UAMY N/A
- SPRO $16.37
- Revenue Growth
- UAMY 28.40
- SPRO 37.01
- 52 Week Low
- UAMY $0.17
- SPRO $1.01
- 52 Week High
- UAMY $2.35
- SPRO $1.89
- Technical
- Relative Strength Index (RSI)
- UAMY 74.22
- SPRO 31.12
- Support Level
- UAMY $1.90
- SPRO $1.12
- Resistance Level
- UAMY $2.35
- SPRO $1.20
- Average True Range (ATR)
- UAMY 0.32
- SPRO 0.04
- MACD
- UAMY 0.09
- SPRO -0.01
- Stochastic Oscillator
- UAMY 83.60
- SPRO 13.67
About UAMY United States Antimony Corporation
United States Antimony Corp is a fully integrated mining, transportation, milling, smelting, and selling company. It has four operating segments: United States Antimony, Mexican antimony, zeolite, and Precious metals. Its products and services include antimony; silver; gold; zeolite products; and storage, handling, & packaging services. The company's geographical segments are the United States, Canada, and Mexico, of which the vast majority of its revenue comes from the United States.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.